💨 Abstract

Novo Nordisk and Valo Health have expanded their 2023 agreement to develop new treatments for cardiometabolic diseases using AI. The partnership aims to develop up to 20 drugs for obesity, type 2 diabetes, and cardiovascular diseases. The deal could potentially yield Valo near-term payments of up to $190 million and milestone payments of $4.6

Courtesy: theprint.in